Global Hematopoietic Agents Market, By Class (Agents for Anemia, Hematopoietic Growth Factors, Others), Indications Iron Deficiency Anemia, Megaloblastic Anemia, Hematopoietic Growth Factors Disorders, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Hematopoietic Agents Market????? Analysis and Size
The global hematopoietic agents market is expected to witness significant growth during the forecast period. Hematopoietic agents market are envisioned to improve the quality and quantity of the blood, by increasing the hemoglobin level and the erythrocytes leucocytes and platelets count. Hematopoietic agents market are typically used in the treatment of anemia. Exhaustion and tiredness, headache, dry and rough skin, restless legs syndrome, neurocognitive dysfunction, hemodynamic instability, and yellow sallow skin are the major symptoms of hematopoiesis disorder.
Data Bridge Market Research analyses a growth rate in the global hematopoietic agents market during the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Hematopoietic Agents Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Class (Agents for Anemia, Hematopoietic Growth Factors, Others), Indications (Iron Deficiency Anemia, Megaloblastic Anemia, Hematopoietic Growth Factors Disorders, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Merck & Co., Inc. (U.S.), AbbVie Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Hikma Pharmaceuticals PLC (U.K.), PHARMACOSMOS A/S (Denmark), Akebia Therapeutics, Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Hematopoiesis is the formation of blood in the body. It is the complex process of proliferation, differentiation and maturation of the cellular components that is erythrocytes, platelets and leucocytes from the bone marrow stem cells. The balanced interaction between the endogenously derived hematopoietic growth factor and exogenously supplied important nutrients such as hematinics regulates the hematopoiesis process.
Global Hematopoietic Agents Market Dynamics
Drivers
- Strategic Alliances
Vendors are concentrating on addressing the issues related with the high cost of research and development activities of therapeutic drugs by collaborating with pharmaceutical companies. They are also increasing their distribution networks through several strategic alliances with other vendors. As a result, developing and commercialization advanced therapies and drugs for lymphopenia is growing. This development is estimated to have a high impact on the market growth. This boost the market growth.
- Rise in Transplants
As per the studies by Worldwide Network for Blood and Marrow Transplantation (WBMT), it is projected that in 2019, nearly 1.5 million HSCTs were performed globally. Over the last two decades, hematopoietic stem cell transplant (HSCT) has seen fast expansion to become the standard of care for several patients with congenital or acquired disorders of the hematopoietic system or with chemo- radio- or, immuno- sensitive malignancies. Thus, this factor boost the market growth.
Opportunities
- Surge in usage in Hospitals
Hospitals and specialty clinics are the biggest consumer of the any type of lymphoma treatment market and it is rising because of the development of more and more hospitals. In addition to this, healthcare companies are also launching new and improved formulations of drugs for lowering the lymphopenia cases. Thus, this higher demand from hospitals for this type of therapeutics is creating opportunities for the market growth.
- Rising Lymphoma Cases
In 2020, as per the International Agency of Research on Cancer (IARC), on a global scale, out of every 100,000 individuals, 336,669 individuals were suffering from leukemia. 64,067 with Hodgkin lymphoma, and 399,610 with non-Hodgkin lymphoma. Hematopoietic stem cells have the capacity to produce more blood cells, such as red blood cells, white blood cells, and platelets. The global hematopoietic agents market is projected to grow based on these factors. This creates more opportunities in the market.
Restraints/Challenges
- Lack of Skilled Professionals
Lack of trained healthcare professionals who are unaware of knowledge of the treatment process could curb the growth of the global hematopoietic agents market over a forecast period.
- Side Effects of Hematopoietic Agents
There are various side effects that may hinder the growth of the market. Adverse effects such as anemia, hair loss, fatigue, and nausea cause the patient’s life difficulties. The diseased condition is severe and thus many of the patients require chemotherapy which can lead to side-effects such as sore mouth, loss of appetite, tiredness, infections and many such factors.
This global hematopoietic agents market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global hematopoietic agents market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Hematopoietic Agents Market Scope
The global hematopoietic agents market is segmented on the basis of class, indications, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Class
- Agents for Anemia
- Hematopoietic Growth Factors
- Others
Indications
- Iron Deficiency Anemia
- Megaloblastic Anemia
- Hematopoietic Growth Factors Disorders
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Hematopoietic Agents Market Regional Analysis/Insights
The global hematopoietic agents market is analyzed and market size insights and trends are provided by class, indications, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global hematopoietic agents market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to the presence of key manufacture of the product, high research & development and healthcare expenditure and skilled professionals.
Asia-Pacific dominates the market due to increased government awareness programs, increased prevalence of iron deficiency in females and presence of the generic manufacturer.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Hematopoietic Agents Market Share Analysis
The global hematopoietic agents market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global hematopoietic agents market.
Key players operating in the global hematopoietic agents market.include:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Merck & Co., Inc. (U.S.)
- AbbVie Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Hikma Pharmaceuticals PLC (U.K.)
- PHARMACOSMOS A/S (Denmark)
- Akebia Therapeutics, Inc. (U.S.)
SKU-